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E D I T O R I A L
Improving outcomes and decreasing costs of neurological 
diseases: Mind the gap
Neurological disorders are the leading cause of disability-adjusted 
life-years (DALYs) and the second leading cause of deaths. The four 
main contributors to neurological DALYs are stroke, migraine, de-
mentia, and meningitis [1]. Global and regional actions to decrease 
this burden are urgently needed. To appropriately set priorities and 
allocate resources for such actions, political leaders need to be in-
formed by epidemiological and health economic studies.
In a timely and commendable initiative, the European Brain 
Council (EBC) launched the Value of Treatment (VoT) for Brain 
Disorders project, with a focus on the benefits of improved health-
care, the identification of treatment gaps along the patient care 
pathway, and the estimation of associated cost savings. The first 
publications resulting from this project appeared recently in the 
European Journal of Neurology, dealing with four disorders: stroke, 
Parkinson's disease (PD), normal-pressure hydrocephalus (NPH) and 
restless legs syndrome (RLS) [2-6].
Barral et al. [2] reported on a cross-sectional survey on loss of 
productivity and informal care costs related to ischemic stroke in a 
regional population-based cohort study. Most patients were retired 
or unemployed, and the response rate was 42%. The mean cost of 
productivity losses was estimated at €7589 ± €12,305 per patient 
in the first post-stroke year, with 5.4%, 71.2%, and 23.4% of these 
being attributed to presenteeism (decreased productivity at work), 
absenteeism, and leisure time, respectively. The annual mean total 
cost of informal care was €10,635 per caregiver. This study illus-
trates how informal care and productivity losses of patients with 
ischemic stroke represent a significant economic burden for society, 
comparable to direct costs. These costs should be included in eco-
nomic evaluations of stroke.
An analysis of the patient pathway for ischemic stroke [3] iden-
tified atrial fibrillation treatment, access to rehabilitation and im-
plementation of Comprehensive Stroke Services as unmet needs. 
Availability of acute endovascular treatment was analysed as a com-
ponent of Comprehensive Stroke Services. Full implementation of 
these services was associated with a 9.8% absolute reduction in the 
risk of dependency or death and was cost-effective. The results of 
this study are relatively robust and are a valid argument for launch-
ing new Comprehensive Stroke Centres and scaling up some existing 
primary stroke centres.
Parkinson's disease affects approximately two in every 1000 
people in Europe. The economic evaluation of PD management 
by Dodel et al. [4] focused on early initiation of treatment, best 
treatment for advanced disease (deep brain stimulation and best 
medical treatment, including pump therapies), and adherence to 
treatment. Filling the current gaps for these interventions was 
found to be cost-effective for all of them. Achieving the target 
adherence to treatment would generate the highest cost savings 
(€239,000–€576,000 in Germany). Greater savings will be ob-
tained when a disease-modifying drug becomes available, because 
PD is already quite advanced when the first symptoms of became 
apparent.
Idiopathic NPH is an important cause of gait, balance, cognitive, 
and sphincter disturbances in elderly people [7]. More than 25% of 
such patients show gait improvement after shunting, but only 50% to 
60% improve in cognition and bladder function [8] Within 30 days, 
25% of shunted patients need hospital admission or experience a 
complication, including intracranial bleeding [6]. The proportion of 
patients receiving shunting is currently low, probably due to a lack of 
awareness and fear of complications among patients and referring 
doctors. These treatment gasps were identified in a care pathway 
analysis by Tinelli et al. [5], who also performed a cost-effectiveness 
analysis of delivering shunt surgery to patients with idiopathic NPH. 
They compared moving from the 25% of patients who undergo sur-
gery nowadays to an ambitious target of 90%. Timely and adequate 
shunting was cost-effective, with a cost per QALY saved of €20,202 
at 5 years and €35,128 at 15 years, although 15 years is an optimistic 
length of survival, considering the median age and comorbidities of 
idiopathic NPH patients [7,9].
For many people with RLS, symptoms are fortunately mild 
or intermittent. Diagnosis is often delayed as symptoms are at-
tributed to other conditions. Trenkwalder et al. [6] estimated that 
the yearly cost of RLS for Germany, France and Italy, for an RLS 
prevalence of 1.6, could reach €2,018,868m. Three treatment 
gaps were identified: delayed diagnosis; insufficient response; 
and augmentation. Economic savings when closing the three 
treatment gaps, were €1600 to €33,300 over a period of 54 years 
for delayed diagnosis, €3600 to €7800 for an 11-year time hori-
zon and €8900 to €36,000 for a 4-year time horizon per patient 
case, for insufficient response and augmentation, respectively. 
Given the high prevalence of RLS, the authors stress the impor-
tance of education for all subspecialities involved in RLS patient 
care and the public. This should also include general practice, as 
the first medical encounter for many patients with RLS will be 
their general practitioner.
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Health economic and patient pathway analyses still face import-
ant methodological limitations, in particular due to the low quality 
of evidence describing patient itinerary and supporting (or not) the 
value of each of its steps. For most neurological diseases, there is, 
in general, high-quality evidence on which to base decisions to per-
form or avoid therapeutic interventions. Unfortunately, this is not 
always the case for diagnostic procedures and processes of care, for 
which we often have to rely only on expert opinions. High-quality 
observational studies and pragmatic trials with generalizable re-
sults are needed to improve the inputs of health economic studies. 
The analytic process for these studies implies a “single chronic dis-
ease” approach. However, comorbidities may make long-term sce-
narios unrealistic, as they compete for the unfavorable outcomes 
and may offset gains obtained by earlier and better diagnosis and 
management.
Increased costs of prolonged later phases of chronic diseases and 
upfront payments to improve facilities and processes of care are re-
garded suspiciously by politicians. Their transient years in office are 
usually shorter than the latency time between intervention and the 
point when health gains are obtained. The responsibility will fall on 
healthcare professionals and scientists to influence the public and pol-
iticians in order to translate the evidence provided by the five studies 
resulting from the EBC project into policies to improve the care and 
outcomes of individuals with chronic neurological disorders [10].
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